4
Changes in Ownership
GeneDx Holdings Corp. Filed Acc 0001689575-26-000024
CHIEF EXECUTIVE OFFICER sold 2,172 shares at an average $65.19 ($141,595)
- CHIEF EXECUTIVE OFFICER acquired 3,874 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-04-29 | Option exercise | +3,874 | 95,388 | D | ||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-04-29 | Sale | −2,154 | $65.20 | $140,441 | 93,234 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-04-29 | Sale | −18 | $64.12 | $1,154 | 93,216 | D |
| Derivatives | |||||||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-04-29 | Option exercise · Restricted Stock Unit | −3,874 | 0 | D | ||
| Open-market sales · 2,172 sh · avg $65.19 · $141,595 | |||||||
Loading xslF345X06/form4-05012026_080508.xml…